FDA wants risk-based draft guidances it published this year to increase industry accountability and free resources for high-risk inspections as the number of foreign-sourced drugs entering the U.S. exceeds the agency's inspection capabilities
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
The Health and Human Services Secretary made incorrect statements about the status of key industry priorities at a recent House hearing, which actually may be a good thing for drug sponsors.
HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.
Industry associations EFPIA, EUCOPE and EURORDIS have praised the European Commission’s newly launched life sciences strategy, which will see investment funnelled into improving the clinical trial ecosystem and supporting advanced therapy development.
